LUCD (Lucid Diagnostics) Quality Rank


LUCD Lucid Diagnostics Inc LUCD
26 GF Score
Price $1.07
GF Value $0.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Lucid Diagnostics Quality Rank Related Terms

LUCD
26GF Score
Lucid Diagnostics Inc LUCD
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81. GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.

Key valuation signals for LUCD:

  • Quality Rank:
  • GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score

Get the complete analysis for LUCD

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price
$0.81
GF Value